

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

TC-32

RRID:CVCL_7151

Type: Cell Line

Proper Citation

RRID:CVCL_7151

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_7151

Proper Citation: RRID:CVCL_7151

Description: Cell line TC-32 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Primitive neuroectodermal tumor

Defining Citation: [PMID:3004699](#), [PMID:3390826](#), [PMID:8040301](#), [PMID:16631476](#), [PMID:22142829](#), [PMID:24312454](#), [PMID:25010205](#), [PMID:25984343](#), [PMID:26351324](#), [PMID:26428435](#), [PMID:26979953](#), [PMID:28196595](#), [PMID:29464090](#), [PMID:30879952](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:36476851](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Ewing Sarcoma Cell Line Atlas (ESCLA)., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: TC-32

Synonyms: TC32

Cross References: BTO:BTO_0004227, BioGRID_ORCS_Cell_line:199, cancercellines:CVCL_7151, Cell_Model_Passport:SIDM01465, ChEMBL-Cells:ChEMBL4295485, ChEMBL-Targets:ChEMBL4296499, Cosmic:759891, Cosmic:1078387, Cosmic:1084513, Cosmic:1718432, Cosmic:2060803, Cosmic:2228244, Cosmic:2294588, DepMap:ACH-001205, GEO:GSM1676322, GEO:GSM1701655, GEO:GSM1899423, GEO:GSM5359712, GEO:GSM5359713, GEO:GSM5359714,

GEO:GSM5359715, GEO:GSM5359716, GEO:GSM5359717, GEO:GSM5362928, GEO:GSM5362929, GEO:GSM5362936, GEO:GSM5362937, GEO:GSM5362944, GEO:GSM5362945, GEO:GSM5364011, GEO:GSM5364012, GEO:GSM5364013, GEO:GSM5364014, GEO:GSM5364015, PharmacDB:TC32_1566_2019, Progenetix:CVCL_7151, PubChem_Cell_line:CVCL_7151, Wikidata:Q54971813

ID: CVCL_7151

Record Creation Time: 20220427T221621+0000

Record Last Update: 20260904T015809+0000

Ratings and Alerts

No rating or validation information has been found for TC-32.

No alerts have been found for TC-32.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Berger HR, et al. (2025) Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. Cancer immunology research, 13(10), 1591.

Randolph ME, et al. (2024) RNA helicase DDX3 regulates RAD51 localization and DNA damage repair in Ewing sarcoma. iScience, 27(2), 108925.

Long AW, et al. (2024) Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma. Journal of hematology & oncology, 17(1), 20.

Turaga SM, et al. (2023) Inducing Mitotic Catastrophe as a Therapeutic Approach to Improve Outcomes in Ewing Sarcoma. Cancers, 15(20).

Randolph ME, et al. (2023) RNA Helicase DDX3 Regulates RAD51 Localization and DNA Damage Repair in Ewing Sarcoma. bioRxiv : the preprint server for biology.

Ramos L, et al. (2023) A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(17), 3541.

Orth MF, et al. (2022) Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation. Cell reports, 41(10), 111761.

Martin JC, et al. (2022) WEE1 inhibition augments CDC7 (DDK) inhibitor-induced cell death in Ewing sarcoma by forcing premature mitotic entry and mitotic catastrophe. *Cancer research communications*, 2(6), 471.

Park JA, et al. (2022) Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies. *Journal for immunotherapy of cancer*, 10(1).

Lin TY, et al. (2021) Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy. *Journal for immunotherapy of cancer*, 9(9).

Yeung C, et al. (2019) Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma. *Cancer research*, 79(19), 5060.